Results 61 to 70 of about 908,554 (203)
Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features [PDF]
, 2018 Diffuse leptomeningeal glioneuronal tumors (DLGNT) represent rare CNS neoplasms which have been included in the 2016 update of the WHO classification. The wide spectrum of histopathological and radiological features can make this enigmatic tumor entity ...Brandner, Sebastian, Brück, Wolfgang, Capper, David, Chiang, Jason, Cruz Martinez, Ofelia, Deng, Maximilian Y., Ebinger, Martin, Ellison, David W., Giangaspero, Felice, Gärtner, Jutta, Hansford, Jordan R., Hartmann, Christian, Hernáiz-Driever, Pablo, Jaunmuktane, Zane, Jones, David T. W., Korshunov, Andrey, Leipold, Alfred, Milde, Till, Monoranu, Camelia-Maria, Mora, Jaume, Morales la Madrid, Andres, Nozza, Paolo, Paulus, Werner, Pfister, Stefan M., Pietsch, Torsten, Rüdiger, Thomas, Sahm, Felix, Schittenhelm, Jens, Schuhmann, Martin U., Sill, Martin, Sommer, Clemens, Stoler, Iris, Tietze, Anna, von Deimling, Andreas, Wittmann, Andrea +34 morecore +1 more sourceDiagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas : expert recommendations from the World Sarcoma Network [PDF]
, 2020 Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new personalized therapies for a ...Antonescu, C. R., Bjerkehagen, B., Blay, J-Y, Bovee, J. V. M. G., Boye, K., Chacon, M., Dei Tos, A. P., Demetri, G. D., Desai, J., Fletcher, J. A., Gelderblom, H., George, S., Gronchi, A., Haas, R. L., Hall, K. Sundby, Hindi, N., Hohenberger, P., Joensuu, H., Jones, R. L., Judson, Ian, Kang, Y-K, Kawai, A., Lazar, A. J., Le Cesne, A., Maestro, R., Maki, Rg, Martin, J., Naito, Y., Patel, S., Penault-Llorca, F., Raut, C. Premanand, Rutkowski, P., Safwat, A., Sbaraglia, M., Schaefer, I-M, Schoffski, P., Serrano, C., Shen, L., Stacchiotti, S., Tap, W. D., Thomas, D. M., Trent, J., Valverde, C., van der Graaf, W. T. A., von Mehren, M., Wagner, A., Wardelmann, E., Zalcberg, J. +47 morecore +5 more sourcesNTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series [PDF]
, 2022 The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of "histology-agnostic" drugs.Capotondi, Barbara, Carlucci, Manuela, Guerriero, Simona, Iannantuono, Giovanni Maria, Riondino, Silvia, Roselli, Mario, Rosenfeld, Roberto, Sganga, Stefano, Torino, Francesco +8 morecore +2 more sourcesNTRK gene aberrations in triple‐negative breast cancer: detection challenges using IHC, FISH, RT‐PCR, and NGS
The Journal of Pathology: Clinical Research, 2023 Triple‐negative breast cancer (TNBC) is usually an aggressive disease with a poor prognosis and limited treatment options. The neurotrophic tyrosine receptor kinase (NTRK) gene fusions are cancer type‐agnostic emerging biomarkers approved by the Food and Federica Zito Marino, Simona Buono, Marco Montella, Rosa Giannatiempo, Francesco Messina, Giovanni Casaretta, Grazia Arpino, Giulia Vita, Francesco Fiorentino, Luigi Insabato, Alessandro Sgambato, Michele Orditura, Renato Franco, Marina Accardo +13 moredoaj +1 more sourceMolecular characterization of cancers with NTRK gene fusions [PDF]
Modern Pathology, 2019 Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently detected in rare cancer types (e.g., secretory breast carcinoma and congenital infantile fibrosarcoma), but the occurrence of NTRK fusions in common cancers and their ...Zoran Gatalica, Joanne Xiu, Jeffrey Swensen, Semir Vranic +3 moreopenaire +4 more sourcesExpert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
Thoracic Cancer, 2022 Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application.Chunwei Xu, Lu Si, Wenxian Wang, Ziming Li, Zhengbo Song, Qian Wang, Aijun Liu, Jinpu Yu, Wenfeng Fang, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Yu Chen, Jingping Yuan, Feng Wang, Zhansheng Jiang, Gen Lin, Xingxiang Pu, Rongbo Lin, Weifeng Liu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Lei Lei, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Junli Xue, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Rui Zhang, Xiao Hu, Jin Zhou, Zhengfei Zhu, Yongheng Li, Hong Qiu, Fan Xia, Yuanyuan Lu, Xiaofeng Chen, Rui Ge, Enyong Dai, Yu Han, Weiwei Pan, Jiancheng Luo, Hongtao Jia, Xiaowei Dong, Fei Pang, Kai Wang, Liping Wang, Youcai Zhu, Yanru Xie, Xinqin Lin, Jing Cai, Jia Wei, Fen Lan, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Bing Wan, Donglai Lv, Qing Wei, Jin Kang, Jiatao Zhang, Chao Zhang, Genhua Yu, Juanjuan Ou, Lin Shi, Zhongwu Li, Zhefeng Liu, Jing Liu, Nong Yang, Lin Wu, Huijuan Wang, Gu Jin, Liu Yang, Guansong Wang, Meiyu Fang, Yong Fang, Yuan Li, Xiaojia Wang, Yiping Zhang, Shenglin Ma, Biyun Wang, Xiaotian Zhang, Yong Song, Yuanzhi Lu +110 moredoaj +1 more sourceSimultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach:A multi-institutional research study [PDF]
, 2018 Contains fulltext :
195300.pdf (publisher's version ) (Open ...A Marchetti, A Uguen, A Vaishnavi, AK Virmani, Aldo Scarpa, Alexander Boag, Andrea Mafficini, Anna Maria Rachiglio, Anne Reiman, Astrid Hirschmann, Bastiaan Tops, Cancer Genome Atlas Research N, Cecily P. Vaughn, D Matsubara, Delphine Le Corre, E Ardini, F Li, Federica Zito Marino, Harriet E. Feilotter, Henriette M. Kurth, Hélène Blons, Ian A. Cree, JF Gainor, José Carlos Machado, José Luis Costa, JP Koivunen, K Rikova, K Takeuchi, Kazuko Sakai, Kazuto Nishio, KD Davies, Kelli Bramlett, KF To, L Ding, L Tembuyser, LM Sholl, M Soda, Marjolijn J. L. Ligtenberg, ME Lira, Michel Bihl, ML Wallander, N Pfarr, Nicola Normanno, Orla Sheils, Pierre Laurent-Puig, RM Phelps, Rosella Petraroli, Roy R. L. Bastien, S Scarpino, SM Ali, Susan Crocker, T Kohno, Varun Bagai, X Gao, Y Pan, Z Dai +55 morecore +5 more sourcesCanadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
Current Oncology, 2021 The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions.D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao +17 moredoaj +1 more sourceRecurrent SPECC1L-NTRK fusions in pediatric sarcoma and brain tumors. [PDF]
Cold Spring Harb Mol Case Stud, 2020 The identification of rearrangements driving expression of neurotrophic receptor tyrosine kinase (NTRK) family kinases in tumors has become critically important because of the availability of effective, specific inhibitor drugs. Whole-genome sequencing (WGS) combined with RNA sequencing (RNA-seq) can identify novel and recurrent expressed fusions. Here Khuong-Quang DA, Brown LM, Wong M, Mayoh C, Sexton-Oates A, Kumar A, Pinese M, Nagabushan S, Lau L, Ludlow LE, Gifford AJ, Rodriguez M, Desai J, Fox SB, Haber M, Ziegler DS, Hansford JR, Marshall GM, Cowley MJ, Ekert PG. +19 moreeuropepmc +5 more sources
